Primarily, early BT non-responders treated with phentermine achieved 5.9% weight loss from randomization to week 24, surpassing the 2.8% loss observed with placebo
Weight Loss and Lean Mass Findings Significant improvements in body composition and anthropometric parameters were observed after GLP-1-based treatment
For GLP-1 non-responders, these barriers can result in prolonged periods of ineffective treatment and unnecessary suffering
Tirzepatide (Mounjaro), a dual GIP/GLP-1 receptor agonist, shows dose-dependent nausea rates, ranging from approximately 12-18% at lower doses to higher rates at doses used for weight management, as demonstrated in the SURPASS-2 trial comparing it with semaglutide
For more than 20 years, Nutrishop has been helping customers crush their health and fitness goals with quality, cutting-edge dietary and nutritional supplements